Marcia C de Oliveira Otto1, Rozenn N Lemaitre2, Xiaoling Song3, Irena B King4, David S Siscovick5, Dariush Mozaffarian6. 1. Division of Epidemiology, Human Genetics and Environmental Sciences, The University of Texas Health Science Center at Houston School of Public Health, Houston, TX. 2. Department of Medicine, University of Washington, Seattle, WA. 3. Public Health Sciences Division, Fred Hutchinson Cancer Research Center, Seattle, WA. 4. Department of Internal Medicine, University of New Mexico, Albuquerque, NM. 5. New York Academy of Medicine, New York, NY. 6. Friedman School of Nutrition Science and Policy, Tufts University, Boston, MA.
Abstract
Background: Controversy has emerged about the benefits compared with harms of dairy fat, including concerns over long-term effects. Previous observational studies have assessed self-reported estimates of consumption or a single biomarker measure at baseline, which may lead to suboptimal estimation of true risk. Objective: The aim of this study was to investigate prospective associations of serial measures of plasma phospholipid fatty acids pentadecanoic (15:0), heptadecanoic (17:0), and trans-palmitoleic (trans-16:1n-7) acids with total mortality, cause-specific mortality, and cardiovascular disease (CVD) risk among older adults. Design: Among 2907 US adults aged ≥65 y and free of CVD at baseline, circulating fatty acid concentrations were measured serially at baseline, 6 y, and 13 y. Deaths and CVD events were assessed and adjudicated centrally. Prospective associations were assessed by multivariate-adjusted Cox models incorporating time-dependent exposures and covariates. Results: During 22 y of follow-up, 2428 deaths occurred, including 833 from CVD, 1595 from non-CVD causes, and 1301 incident CVD events. In multivariable models, circulating pentadecanoic, heptadecanoic, and trans-palmitoleic acids were not significantly associated with total mortality, with extreme-quintile HRs of 1.05 for pentadecanoic (95% CI: 0.91, 1.22), 1.07 for heptadecanoic (95% CI: 0.93, 1.23), and 1.05 for trans-palmitoleic (95% CI: 0.91, 1.20) acids. Circulating heptadecanoic acid was associated with lower CVD mortality (extreme-quintile HR: 0.77; 95% CI: 0.61, 0.98), especially stroke mortality, with a 42% lower risk when comparing extreme quintiles of heptadecanoic acid concentrations (HR: 0.58; 95% CI: 0.35, 0.97). In contrast, heptadecanoic acid was associated with a higher risk of non-CVD mortality (HR: 1.27; 95% CI: 1.07, 1.52), which was not clearly related to any single subtype of non-CVD death. No significant associations of pentadecanoic, heptadecanoic, or trans-palmitoleic acids were seen for total incident CVD, coronary heart disease, or stroke. Conclusions: Long-term exposure to circulating phospholipid pentadecanoic, heptadecanoic, or trans-palmitoleic acids was not significantly associated with total mortality or incident CVD among older adults. High circulating heptadecanoic acid was inversely associated with CVD and stroke mortality and potentially associated with higher risk of non-CVD death.
Background: Controversy has emerged about the benefits compared with harms of dairy fat, including concerns over long-term effects. Previous observational studies have assessed self-reported estimates of consumption or a single biomarker measure at baseline, which may lead to suboptimal estimation of true risk. Objective: The aim of this study was to investigate prospective associations of serial measures of plasma phospholipid fatty acidspentadecanoic (15:0), heptadecanoic (17:0), and trans-palmitoleic (trans-16:1n-7) acids with total mortality, cause-specific mortality, and cardiovascular disease (CVD) risk among older adults. Design: Among 2907 US adults aged ≥65 y and free of CVD at baseline, circulating fatty acid concentrations were measured serially at baseline, 6 y, and 13 y. Deaths and CVD events were assessed and adjudicated centrally. Prospective associations were assessed by multivariate-adjusted Cox models incorporating time-dependent exposures and covariates. Results: During 22 y of follow-up, 2428 deaths occurred, including 833 from CVD, 1595 from non-CVD causes, and 1301 incident CVD events. In multivariable models, circulating pentadecanoic, heptadecanoic, and trans-palmitoleic acids were not significantly associated with total mortality, with extreme-quintile HRs of 1.05 for pentadecanoic (95% CI: 0.91, 1.22), 1.07 for heptadecanoic (95% CI: 0.93, 1.23), and 1.05 for trans-palmitoleic (95% CI: 0.91, 1.20) acids. Circulating heptadecanoic acid was associated with lower CVD mortality (extreme-quintile HR: 0.77; 95% CI: 0.61, 0.98), especially stroke mortality, with a 42% lower risk when comparing extreme quintiles of heptadecanoic acid concentrations (HR: 0.58; 95% CI: 0.35, 0.97). In contrast, heptadecanoic acid was associated with a higher risk of non-CVD mortality (HR: 1.27; 95% CI: 1.07, 1.52), which was not clearly related to any single subtype of non-CVD death. No significant associations of pentadecanoic, heptadecanoic, or trans-palmitoleic acids were seen for total incident CVD, coronary heart disease, or stroke. Conclusions: Long-term exposure to circulating phospholipidpentadecanoic, heptadecanoic, or trans-palmitoleic acids was not significantly associated with total mortality or incident CVD among older adults. High circulating heptadecanoic acid was inversely associated with CVD and stroke mortality and potentially associated with higher risk of non-CVD death.
Authors: Lieke Gijsbers; Eric L Ding; Vasanti S Malik; Janette de Goede; Johanna M Geleijnse; Sabita S Soedamah-Muthu Journal: Am J Clin Nutr Date: 2016-02-24 Impact factor: 7.045
Authors: Dariush Mozaffarian; Marcia C de Oliveira Otto; Rozenn N Lemaitre; Amanda M Fretts; Gokhan Hotamisligil; Michael Y Tsai; David S Siscovick; Jennifer A Nettleton Journal: Am J Clin Nutr Date: 2013-02-13 Impact factor: 7.045
Authors: Sabina Sieri; Vittorio Krogh; Pietro Ferrari; Franco Berrino; Valeria Pala; Anne C M Thiébaut; Anne Tjønneland; Anja Olsen; Kim Overvad; Marianne Uhre Jakobsen; Francoise Clavel-Chapelon; Veronique Chajes; Marie-Christine Boutron-Ruault; Rudolf Kaaks; Jakob Linseisen; Heiner Boeing; Ute Nöthlings; Antonia Trichopoulou; Androniki Naska; Pagona Lagiou; Salvatore Panico; Domenico Palli; Paolo Vineis; Rosario Tumino; Eiliv Lund; Merethe Kumle; Guri Skeie; Carlos A González; Eva Ardanaz; Pilar Amiano; María José Tormo; Carmen Martínez-García; Jose R Quirós; Göran Berglund; Bo Gullberg; Göran Hallmans; Per Lenner; H Bas Bueno-de-Mesquita; Fränzel J B van Duijnhoven; Petra H M Peeters; Carla H van Gils; Timothy J Key; Francesca L Crowe; Sheila Bingham; Kay Tee Khaw; Sabina Rinaldi; Nadia Slimani; Mazda Jenab; Teresa Norat; Elio Riboli Journal: Am J Clin Nutr Date: 2008-11 Impact factor: 7.045
Authors: Hilary J Bethancourt; Kelsey A Schmidt; Gail Cromer; Maggie S Burhans; Jessica N Kuzma; Derek K Hagman; Imashi Fernando; Merideth Murray; Kristina M Utzschneider; Sarah Holte; Ross L Prentice; Jana Kraft; Mario Kratz Journal: Am J Clin Nutr Date: 2022-06-07 Impact factor: 8.472
Authors: Kristin M Hirahatake; Arne Astrup; James O Hill; Joanne L Slavin; David B Allison; Kevin C Maki Journal: Adv Nutr Date: 2020-05-01 Impact factor: 8.701
Authors: Mary Catherine Sawh; Martina Wallace; Emma Shapiro; Nidhi P Goyal; Kimberly P Newton; Elizabeth L Yu; Craig Bross; Janis Durelle; Cynthia Knott; Jon A Gangoiti; Bruce A Barshop; Jivani M Gengatharan; Noah Meurs; Alexandra Schlein; Michael S Middleton; Claude B Sirlin; Christian M Metallo; Jeffrey B Schwimmer Journal: J Pediatr Gastroenterol Nutr Date: 2021-04-01 Impact factor: 2.839
Authors: Kamalita Pertiwi; Leanne K Küpers; Anne J Wanders; Janette de Goede; Peter L Zock; Johanna M Geleijnse Journal: Nutr Metab (Lond) Date: 2019-11-13 Impact factor: 4.169